The FDA Just Cleared the First US Ibogaine Trial. It Took 30 Years.

---

title: “The FDA Just Cleared the First US Ibogaine Trial. It Took 30 Years.” slug: noribogaine-fda-ind-clearance-alcohol-2026 post_type: daily_pulse primary_category: science-medicine substance_category: alcohol lens: [science, treatment] tags: [ibogaine, alcohol, fda, clinical-trial, psychedelic-therapy] meta_description: “DemeRx received FDA clearance for the first US clinical trial of noribogaine—an ibogaine metabolite—for alcohol use disorder. Dr. Deborah Mash has been waiting 30 years for this moment.” read_time_minutes: 3 schema_type: NewsArticle sources:

• url: https://rainierrehab.org/blog/2026-04-25-fda-first-us-ibogaine-trial-alcohol-use-disorder title: “FDA Clears First US Ibogaine Trial for Alcohol Use Disorder” publisher: Rainier Rehab (citing DemeRx announcement) source_tier: B published_date: 2026-04-25
• url: https://www.biospace.com/drug-development/despite-fda-trial-clearance-ibogaine-metabolite-wont-receive-red-carpet-treatment title: “Despite FDA trial clearance, ibogaine metabolite won’t receive red carpet treatment” publisher: BioSpace source_tier: B published_date: 2026-04-26
• url: https://www.medscape.com/viewarticle/ibogaine-psychiatric-illness-federal-policy-push-meets-2026a1000dvc title: “Ibogaine for Psychiatric Illness: Federal Policy Push Meets Safety Concerns” publisher: Medscape source_tier: B ai_generated: true

---

Deborah Mash, PhD, began researching ibogaine’s ability to interrupt addiction in the early 1990s at the University of Miami. She had a clear mechanism hypothesis: the compound—derived from the root bark of the Tabernanthe iboga shrub, used for centuries in central African healing ceremonies—appeared to reset mu-opioid receptor signaling in ways that dramatically reduced withdrawal symptoms and cravings. She had early data. She also had, by approximately 1993, no federal funding to continue. The government fighting a war on drugs was not interested in a Schedule I substance that interrupted addiction through a twelve-to-thirty-six-hour visionary experience.

She kept going. Research moved offshore—to clinics in Mexico, Canada, and the Netherlands where patients with opioid use disorder, alcohol use disorder, and stimulant dependence were paying out of pocket for ibogaine-assisted treatment that couldn’t legally happen in the United States. The evidence accumulated in the gray margins: anecdotal at first, then observational, then small studies. In 2023, a Stanford study of ibogaine treatment in special operations veterans with traumatic brain injury and PTSD showed dramatic reductions in PTSD symptoms, depression, and disability. The results were stunning enough to force the question: why is this only available in Tijuana?

On April 25, 2026, DemeRx NB announced FDA clearance of an Investigational New Drug application for noribogaine hydrochloride—the primary metabolite of ibogaine. Noribogaine is what the body converts ibogaine into; it may have a safer profile than the parent compound and produces less intense psychedelic effects, which both reduces the experience burden for patients and lowers the monitoring requirements that make ibogaine-assisted treatment logistically complex. The Phase I trial, directed by Mash, will enroll healthy volunteers first to establish safety parameters before any patient exposure. The target condition is alcohol use disorder, which affects roughly 29 million Americans and kills more than 140,000 people annually.

This is not approval. It is not remotely close to approval. A Phase I safety study with healthy volunteers is the first step in a regulatory process that typically spans five to ten years. Noribogaine remains a Schedule I substance throughout that process, which creates friction at every subsequent phase. And the cardiac concern associated with ibogaine is real: documented cases of potentially fatal arrhythmias have been linked to both the parent compound and its metabolite, particularly in patients with underlying cardiac conditions. The Phase I trial must characterize this risk carefully before any patient exposure can proceed.

But an IND clearance is how every approval begins. It is the door that opens all the other doors. For thirty years, that door was closed—not because the evidence was absent, but because the federal classification system made generating evidence nearly impossible, and the political environment made even trying it radioactive. An executive order directing the FDA to accelerate evaluation of psychedelic treatments with Breakthrough Therapy Designations has begun to shift that. Not quickly. Not without the safety work the evidence base actually demands. But measurably.

For people with treatment-resistant alcohol use disorder—people who have been through inpatient detox, outpatient therapy, naltrexone, acamprosate, and the revolving door that connects them—a Phase I healthy-volunteer trial is a long road from treatment. What Mash and DemeRx have is permission to find out. In the context of the last thirty years, that is not a small thing.